Skip to Main Content
Contribute Try STAT+ Today

One approach federal lawmakers have used to jumpstart certain types of drug development has been to offer vouchers to companies that can later be redeemed when seeking approval for yet another medicine. But a new analysis suggests the notion may not be worth the cost if it were used to entice drug makers to develop much-needed antibiotics.

Citing a bill proposed last year to offer vouchers for new antibiotics, the researchers calculated the idea would have cost an extra $4.5 billion in spending on medicines over a 10-year period, had the legislation taken effect in 2007. The excess cost was attributed to the added exclusivity drug makers would have received for medicines that would have otherwise faced competition from lower-cost generics, according to the analysis published in Clinical Infectious Diseases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.